Abstract
Circulating myeloid (CFU-GM) and erythroid (BFU-E) progenitor levels were evaluated weekly throughout 3 courses of treatment with vinorelbine (VNB) ifosfamide (IFO) and filgrastim (G-CSF) with or without addition of cisplatin (DDP) in 20 stage IIIB or IV non small-cell lung cancer patients. In IFO, VNB, DDP-treated patients, BFU-E mobilization in peripheral blood following chemotherapy and G-CSF was completely lacking, in contrast with the patients treated with IFO, VNB plus G-CSF. CFU-GM release, however, was of the same order in the 2 groups of patients. Further investigations are needed to explain why presence of DDP in this chemotherapeutic protocol hinders erythroid progenitor release in peripheral blood.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy
-
Cell Count
-
Cisplatin / administration & dosage
-
Cisplatin / pharmacology*
-
Erythrocyte Indices
-
Erythroid Precursor Cells / cytology
-
Erythroid Precursor Cells / drug effects*
-
Granulocyte Colony-Stimulating Factor / administration & dosage
-
Hematopoietic Stem Cell Mobilization*
-
Humans
-
Ifosfamide / administration & dosage
-
Leukocyte Count
-
Lung Neoplasms / drug therapy
-
Stem Cells / cytology
-
Vinblastine / administration & dosage
-
Vinblastine / analogs & derivatives
-
Vinorelbine
Substances
-
Antineoplastic Agents, Alkylating
-
Antineoplastic Agents, Phytogenic
-
Granulocyte Colony-Stimulating Factor
-
Vinblastine
-
Cisplatin
-
Vinorelbine
-
Ifosfamide